Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising.
- Workplace substance misuse costs U.S. employers over $81 billion annually through lost productivity, accidents, healthcare costs, and liability, with studies indicating that up to 40% of industrial workplace fatalities involve alcohol misuse.
- MindBio is introducing the world’s first AI-powered voice analytics system to detect drug and alcohol impairment in real time, initially targeting the South American mining sector, where heavy machinery and remote operations make safety monitoring critical.
- Such advanced screening technology has relevance to a global market spanning a range of safety-sensitive industries, including mining, construction, and aviation.
Industrial employers across the world face a persistent challenge: ensuring workers operating heavy machinery or performing safety-critical tasks are not impaired by drugs or alcohol. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is addressing that problem with a technology more commonly associated with consumer devices than workplace safety: artificial intelligence-driven speech analysis.
The biotechnology company, which has spent several years conducting research into intoxication detection, has developed a voice-based AI system designed to identify signs of alcohol or drug impairment within seconds, the first of its kind in the world. Instead of relying on traditional biological testing methods such as breathalyzers or laboratory samples, MindBio’s technology analyzes acoustic patterns in speech to estimate intoxication levels.
The platform is being developed for enterprise use, with the company currently preparing a hardware kiosk system that can screen workers as they enter industrial facilities. The kiosk will prompt workers to speak briefly, allowing the AI model to evaluate voice characteristics associated with intoxication.
The company’s technology analyzes more than 140 speech parameters and processes them through machine-learning models trained on more than 50 million data points. According to MindBio, early testing has shown prediction accuracy above 85% for blood alcohol concentration estimation and roughly 88% accuracy for intoxication classification.
The potential market for such systems reflects the scale of workplace substance misuse. Research published by organizations including the U.S. Department of Labor estimates that substance abuse costs American employers more than $81 billion each year, driven by lost productivity, workplace accidents, healthcare expenses and legal liabilities. (https://ibn.fm/3bv3C).
Approximately 9% of full-time workers in the United States meet the criteria for a substance use disorder each year, according to those estimates. Workers struggling with substance misuse often operate at significantly reduced efficiency. Studies cited by addiction research groups suggest impaired employees may function at around 70% of their normal capacity, creating operational delays and higher error rates.
The financial impact goes beyond productivity losses. It is estimated that each employee with a substance abuse problem can cost an employer between $8,000 and $12,000 annually in combined productivity losses, healthcare spending and accident-related expenses.
For industries dependent on safety and reliability, the risks are particularly acute. Workers who misuse drugs or alcohol are estimated to be 3.6 times more likely to be involved in workplace accidents. Alcohol alone is believed to contribute to roughly 40% of industrial workplace fatalities, underscoring the legal and financial exposure companies face when impairment goes undetected.
MindBio’s early commercial focus reflects those risks. The company is concentrating first on mining operations in South America, a sector characterized by large workforces operating heavy machinery in remote environments. In Chile, for example, data referenced by the company indicates alcohol consumption among mining workers exceeds 75%, with roughly 40% classified as problem drinkers. Such statistics illustrate why impairment screening has become a priority for mining companies operating large industrial sites.
Traditional testing systems typically rely on breathalyzers, urine testing or laboratory blood analysis. These approaches can require specialized staff, laboratory processing or waiting periods that slow down shift changes and facility entry. MindBio’s proposed kiosk system streamlines the process. Workers would simply speak into a terminal at the worksite entrance. The Edge AI device processes the voice sample locally and delivers a rapid screening result, potentially allowing companies to identify impaired workers without delaying operations. Field testing of the kiosk platform is expected to begin in the second quarter of 2026.
The company’s approach relies on acoustic biomarkers: subtle features in speech patterns that change as alcohol or drugs affect cognitive and motor function. Machine learning models analyze these speech features, including rhythm, frequency variations and articulation changes. Because voice samples can be captured quickly through standard microphones, the system can theoretically scale across both enterprise and consumer applications. Alongside the enterprise platform, MindBio also offers a consumer application called Booze AI, which allows individuals to estimate blood alcohol concentration using a smartphone or web interface.
While mining represents an initial market, the broader opportunity may lie in other safety-critical sectors. Construction, aviation, transportation and energy industries all face similar challenges related to impairment detection. In these environments, employers often face strict regulatory requirements regarding alcohol and drug policies.
Workplace research indicates heavy drinking rates reach 17.5% among mining workers and 16.5% among construction employees, significantly higher than many other industries. These sectors also carry high accident costs. Construction workers, for example, experience some of the highest rates of job-related injury and overdose deaths among all professions. MindBio’s technology could potentially fit within a much larger global market centered on occupational safety and regulatory compliance.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN